Public-registry site landscape for NCT07717905, a Chronic Spontaneous Urticaria study sponsored by Bambusa Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07717905 (registry record) |
| Sponsor | Bambusa Therapeutics |
| Condition(s) | Chronic Spontaneous Urticaria |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 10 |
| Site countries | China |
At The Second Affiliated Hospital of Wannan Medical College — one of the facilities listed on this trial — 1 other study is actively recruiting Chronic Spontaneous Urticaria patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07717905 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →